Dose 30 patients in the BEACON trial
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 13 Jan 2025
- Due
- 30 Jun 2025
- Delivered
- July 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Dose 30 patients by mid-2025”
What we found
Evidence strength A What the grades mean
The company announced in August 2025 that it had completed dosing 30 patients in the BEACON trial in July 2025, which occurred after the mid-2025 deadline.
-
A Beam Therapeutics Inc. 8-K filed 2025-08-05
“In July, Beam completed dosing of 30 patients in the BEACON Phase 1/2 study” ✓ confirmed on the page
Market reaction: the shares moved -6.8% against the S&P 500 over the three sessions around the disclosure (4 Aug 2025 to 7 Aug 2025). What this measures
Checked 2 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Scope drift 0.0%
- 2 versions
-
Version 1 · original · stated 13 Jan 2025
Deadline 30 Jun 2025 (“mid-2025”) · target 30 patients
-
Version 2 · stated 6 May 2025
Deadline 30 Jun 2025 (“by mid-2025”) · target 30 patients · wording expected
“Beam expects to dose 30 patients in the BEACON Phase 1/2 clinical trial of BEAM-101 in adults with severe SCD by mid-2025.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Dose
- Deliverable
- BEAM-101 SCD BEACON trial patients
- Target
- 30 patients
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Beam Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-BEAM-003291 · Corrections policy